首页> 美国卫生研究院文献>Case Reports in Oncology >A Case of Poorly Differentiated Large-Cell Neuroendocrine Carcinoma of the Cecum: A Rare Malignancy with Review of the Literature
【2h】

A Case of Poorly Differentiated Large-Cell Neuroendocrine Carcinoma of the Cecum: A Rare Malignancy with Review of the Literature

机译:盲肠分化差的大细胞神经内分泌癌一例:罕见恶性肿瘤并文献复习

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Poorly differentiated neuroendocrine carcinomas (NECs) are rare tumors that can arise anywhere along the gastrointestinal tract. They often present in advanced stage and portend a poor prognosis when compared to adenocarcinomas of the same stage. Characterization of these tumors is best accomplished with tissue biopsy, as peripheral tumor markers commonly used in NECs are of little utility. Therapeutic strategies often involve chemotherapeutic regimens that have been used to treat small-cell lung cancer. Recent studies have shown that programmed death-ligand 1 (PD-L1) expression within poorly differentiated NECs is a poor prognostic indicator. However, PD-L1 expression may represent a possible target for immunotherapy drugs, often called checkpoint inhibitors, such as anti-PD-1 inhibitors.
机译:分化差的神经内分泌癌(NEC)是罕见的肿瘤,可能会在胃肠道的任何地方出现。与同一时期的腺癌相比,它们通常处于晚期,预后不良。这些肿瘤的表征最好通过组织活检来完成,因为NEC中常用的外周肿瘤标记物几乎没有用处。治疗策略通常涉及已用于治疗小细胞肺癌的化疗方案。最近的研究表明,在分化差的NECs中程序性死亡配体1(PD-L1)的表达是不良的预后指标。但是,PD-L1表达可能代表免疫治疗药物的可能靶标,通常被称为检查点抑制剂,例如抗PD-1抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号